Another great part of #ASCO14 ... Got to visit my brother (I am the one with the hair)

Even bigger! #planespotting #ohare #ord #chicago #asco14 #iflyalaska http://instagram.com/p/oy3wgLKviI/

At #ohare and ready to head home. See you next year, #Chicago! #asco14 #iflyalaska

The only thing that could make this last day of #ASCO14 better would be getting an upgrade from @AlaskaAir on the flight home #iflyalaska

Closing thoughts on the use of adoptive T-cell therapy for epithelial tumors. "It's the antigen, stupid!" #ASCO14

Upside of this approach: NK cell engagement and ADCC. Combo with checkpoint inhibitors = be careful. #ASCO14

Pfizer isn't only CD137/4-1BB drug tested. BMS has one.Shows toxicity of immuno activators. Harder than PD-1 #ASCO14

Well, that's the last data talk for me for #ASCO14 . Hope I did you proud @MaverickNY.

Hinrichs: limitations of this small pilot study. #ASCO14

Trying to understand the implications of the HPV-targeted ACT responses for prob of success of CAR-T in epithelial tumors. Thoughts? #asco14

Hinrichs: why does this therapy work in some HPV+ but not others? #ASCO14

And here is your CT scan to show what it looks like. #ASCO14

Kinetics of response to HPV-targeted ACT #ASCO14

Hinrichs: responses seen in cervical cancer - 3 responses, two prolonged CRs. #ASCO14

Now up: adoptive cellular therapy for HPV+ cervical cancer. Still an impt population to serve. #ASCO14

Well, at least Merkel cell cancer didn't get left out this year #ASCO14

CD137 + ritux in NHL combo planned #ASCO14

Not nearly as exciting swimmers plot for PF-05082566/CD137 when it follows PD-1. #ASCO14

Clearly way better tolerated than an CD40 drug. But little response seen. #ASCO14

Worst part of immuno activators: having to start at the MABEL. Long dose esc, requiring novel trial designs. #ASCO14

CD137/4-1BB is actually Pfizers second attempt at immuno activation. They had a CD40 partial agonist Ab that they killed. #ASCO14

As we get close to the end of #ASCO14 I have to send a shout out to #asco who significantly stepped up the WiFi quality this year!

And finally, this will be an interesting case to see if FDA and EMA have different views of need for in vitro diagnostic for PD-1 #ASCO14

Also, cost of PD-1 drugs may influence regulator and payor views of value of patient selection on imperfect biomarker like PD-L1. #ASCO14

Agree strongly with audience question that having the PD-L1 expression data would help with decision to retreat with PD-1 #ASCO14

Surprised that nobody is asking if the FDA has informed the companies as to whether or not PD-L1 would be needed an in vitro dx? #asco14

Callahan: Immune system too complicated for a single biomarker. #ASCO14

PD-L1 not the same as BRAF. Not ready to be used to determine eligibility for PD-1 inhibitor therapy. #ASCO14

Hodi: RECIST alone insufficient response criteria for this class of therapeutics. #ASCO14 #immunotherapy

Wow. Big response following Pembro retreatment despite pseudoprogression #asco14 #NeverSayDie